2012-09-11 13:35:31 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Cyclacel Pharmaceuticals Inc and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Cyclacel Pharmaceuticals Inc (CYCC). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Cyclacel Pharmaceuticals Inc investor.
Report Summary: Cyclacel Pharmaceuticals Inc is a low quality company with a neutral outlook. Cyclacel Pharmaceuticals Inc has weak business growth and is run by inefficient management. The trend in Cyclacel Pharmaceuticals Inc fair value exchange rate against its closest rated-competitor, Insmed Incorporated, has been stable over the past 2 weeks. When compared to its closest competitor, Cyclacel Pharmaceuticals Inc shows less undervaluation and is equally likely to underperform the market.
The 3-page report breaks down the Total StockMark into its three components
– business, management and price, performing an in-depth analysis of Cyclacel Pharmaceuticals Inc for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.